---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-24-000040"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:21:02.504041+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q3 net loss $16.8M; ALTO-100 fails Phase 2b MDD primary endpoint

## Summary
- Net loss of $16.8M in Q3 2024 vs $9.1M a year ago; R&D expense $13.1M, G&A $5.8M.
- Cash, cash equivalents & restricted cash ~$182M expected to fund operations into 2027.
- ALTO-100 Phase 2b MDD missed primary endpoint; biomarker-positive mITT (n=196) not significant.
- Adjunctive subgroup (n=61) showed clinically meaningful effect (Cohen's d=0.47, p=0.09); no MDD advancement planned.
- Timelines: ALTO-300 & ALTO-203 topline 1H 2025; ALTO-101 topline 2H 2025; ALTO-100 bipolar depression topline 2026.

## SEC filing metadata
- accession: 0001999480-24-000040
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/0001999480-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000040/alto-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-24-000040
- JSON: https://secwatch.observer/filing/0001999480-24-000040.json
- Plain text: https://secwatch.observer/filing/0001999480-24-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.